A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental Vitiligo
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Adolescent and Adult Subjects With Non-segmental Vitiligo
Minghui Pharmaceutical (Hangzhou) Ltd
405 participants
Aug 4, 2026
INTERVENTIONAL
Conditions
Summary
This is a randomized, double-blind, multicenter, placebo-controlled clinical study intended to evaluate the efficacy, safety and population pharmacokinetic profiles of MH004 ointment in eligible participants with NSV.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
MH004 1% ointment applied topically to the affected area as a thin film twice a day (BID).
MH004 Placebo ointment applied topically to the affected area as a thin film twice a day (BID).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07682506